Tandem Diabetes Care Inc
NASDAQ:TNDM
Net Margin
Tandem Diabetes Care Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Tandem Diabetes Care Inc
NASDAQ:TNDM
|
1.2B USD |
-10%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
224.5B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
184.2B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
151B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
140.2B USD |
13%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
107.8B USD |
13%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
52.9B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.8B USD |
8%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.7B USD |
75%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
260.4B CNY |
33%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
35.5B USD |
23%
|
Tandem Diabetes Care Inc
Glance View
Tandem Diabetes Care Inc., a prominent figure in the healthcare sector, has carved out a notable niche with its innovative diabetes management solutions. Founded in 2006 and headquartered in San Diego, California, the company has become a leader in providing advanced insulin pump technologies. Central to Tandem’s business model is their flagship product, the t:slim X2 Insulin Pump, a sleek and user-friendly device praised for its ease of use and functionality. Through meticulous engineering and design, Tandem has positioned itself at the forefront of modern diabetes management by enhancing user experience and integrating advanced technologies such as continuous glucose monitoring (CGM) compatibility, making diabetes care more dynamic and responsive. Revenue for Tandem Diabetes Care primarily flows from the sale of these insulin pumps, along with associated supplies and accessories, which are crucial for ongoing diabetes management. The company also generates income through software and technology upgrades. By offering a subscription-based model, Tandem ensures steady revenue from the continual acquisition of consumables and technology updates, fostering customer loyalty and long-term engagement. Their commitment to innovation and patient-centric solutions has not only allowed them to tap into a growing market of diabetes patients seeking improved quality of life but has also strengthened their competitive edge in a rapidly evolving healthcare landscape.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Tandem Diabetes Care Inc's most recent financial statements, the company has Net Margin of -10.2%.
You don't have any saved screeners yet